International Clinical Trial: A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780604) titled 'A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS' on Aug. 19.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Galimedix Therapeutics Inc

Condition: Healthy Adult Participants

Intervention: Drug: Uncoated GAL-101 Salt 1170 mg Drug: Placebo Drug: Enteric-Coated Capsules 195 mg Drug: Enteric-Coated Capsules 390 mg Drug: Uncoated GAL-101 Salt 780 mg Drug:...